Patents by Inventor Indrajit Das

Indrajit Das has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220313628
    Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.
    Type: Application
    Filed: May 24, 2022
    Publication date: October 6, 2022
    Applicant: United Kingdom Research and Innovation
    Inventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEIDER, Anna Gudny SIGURDARDOTTIR
  • Patent number: 11364211
    Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: June 21, 2022
    Assignee: United Kingdom Research and Innovation
    Inventors: Anne Bertolotti, Indrajit Das, Agnieszka Krzyzosiak, Adrien Rousseau, Kim Schneider, Anna Gudny Sigurdardottir
  • Patent number: 11337941
    Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: May 24, 2022
    Assignee: United Kingdom Research and Innovation
    Inventors: Anne Bertolotti, Indrajit Das, Agnieszka Krzyzosiak, Adrien Rousseau, Kim Schneider, Anna Gudny Sigurdardottir
  • Patent number: 11331286
    Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: May 17, 2022
    Assignee: United Kingdom Research and Innovation
    Inventors: Anne Bertolotti, Indrajit Das, Agnieszka Krzyzosiak, Adrien Rousseau, Kim Schneider, Anna Gudny Sigurdardottir
  • Patent number: 11154519
    Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: October 26, 2021
    Assignee: United Kingdom Research and Innovation
    Inventors: Anne Bertolotti, Indrajit Das, Agnieszka Krzyzosiak, Adrien Rousseau, Kim Schneider, Anna Gudny Sigurdardottir
  • Publication number: 20200297668
    Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.
    Type: Application
    Filed: February 28, 2020
    Publication date: September 24, 2020
    Applicant: Medical Research Council
    Inventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEIDER, Anna Gudny SIGURDARDOTTIR
  • Publication number: 20200197337
    Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Applicant: Medical Research Council
    Inventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEIDER, Anna Gudny SIGURDARDOTTIR
  • Publication number: 20180125801
    Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.
    Type: Application
    Filed: April 8, 2016
    Publication date: May 10, 2018
    Applicant: MEDICAL RESEARCH COUNCIL
    Inventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEIDER, Anna Gudny SIGURDARDOTTIR
  • Publication number: 20180111896
    Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.
    Type: Application
    Filed: April 8, 2016
    Publication date: April 26, 2018
    Applicant: MEDICAL RESEARCH COUNCIL
    Inventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEDIDER, Anna Gudny SICURDARDOTTIR
  • Publication number: 20140371137
    Abstract: The present invention relates to methods and compositions pertaining to conjugates comprising a nucleic acid oligomer conjugated to a glucosamine or a derivative thereof which are useful for inhibiting the transcription of target nucleic acids. The conjugates of the invention exhibit advantageous bioavailability and readily penetrate cell membranes which make them useful for inhibiting translation of target mRNA in vivo.
    Type: Application
    Filed: June 13, 2014
    Publication date: December 18, 2014
    Inventors: Virendra Pandey, Jean-Luc Decout, Indrajit Das, Jerome Desire